Neuropeptide B and Neuropeptide W: GPR7/GPR8 Orexigenic System in Energy Balance and Immune Modulation

# Neuropeptide B and Neuropeptide W: GPR7/GPR8 Orexigenic System in Energy Balance and Immune Modulation

The neuropeptide Y (NPY) receptor superfamily — GPCRs that bind the structurally related peptides NPY, PYY, and pancreatic polypeptide — is one of the most extensively studied neuropeptide receptor families in vertebrates, with five receptors (Y1-Y5) governing appetite, anxiety, cardiovascular function, and bone metabolism. Two orphan receptors with sequence homology to this family — GPR7 and GPR8 — remained without identified endogenous ligands until 2002, when neuropeptide B (NPB) and neuropeptide W (NPW) were discovered simultaneously by multiple groups as the GPR7/GPR8 ligands. This guide covers the discovery of NPB and NPW, their receptor pharmacology, neuroanatomical distribution, and their established and emerging roles in energy balance, stress responses, reproductive axis regulation, and immune modulation.

Discovery: Simultaneous 2002 Identification by Multiple Groups

The discovery of NPB and NPW exemplifies the orphan receptor deorphanization era of the early 2000s, when systematic screening of tissue extracts against orphan GPCRs rapidly populated the neuropeptide landscape.

Shimomura et al. (2002) BBRC/JBC: Working at Takeda Chemical Industries, this team characterized GPR7 and GPR8 expression patterns and screened hypothalamic extracts to identify their ligands. They reported two novel peptides — one from bovine hypothalamus with a C-terminus containing -RLRFamide (an RFamide motif) and another with -RMRFamide — and initially proposed these as RFamide-related peptides before the final NPB/NPW nomenclature was established.

Brezillon et al. (2003) and parallel work by Tanaka et al. (2003): Independent groups confirmed GPR7 as the primary receptor for both peptides. The receptor nomenclature settled on NPBWR1 (neuropeptide B/W receptor 1 = GPR7) and NPBWR2 (= GPR8) in current IUPHAR nomenclature.

Key discovery papers:

• •Shimomura Y, Harada M, Goto M, et al. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem. 2002;277(39):35826-35832. PMID: 12130646

Peptide Structure: NPB and NPW Family Members

Both NPB and NPW are produced as N-terminally extended precursors that are proteolytically processed to yield multiple bioactive forms.

Neuropeptide B (NPB):

• •NPB-23: The primary 23-amino acid form; sequence: Tyr-Gln-Ala-Gly-His-Gly-His-Gly-His-Gly-His-Gly-His-Gln-Ala-Gly-His-Gly-His-Gly-His-Arg-Phe-NH₂ (simplified representation — actual sequence varies by species)
• •NPB-29: N-terminally extended 29-amino acid form retaining the same C-terminal sequence
• •Key feature: Brominated tyrosine at position 1 — a post-translational modification unique among neuropeptides. The N-terminal tyrosine of NPB carries a bromine atom at the ortho position of the phenol ring (bromotyrosine or Br-Tyr). This modification is absent in NPW.
• •Gene: NPB (human chr 11q12.2)

Neuropeptide W (NPW):

• •NPW-23: Primary 23-amino acid form; similar C-terminal -RFamide structure
• •NPW-30: N-terminally extended 30-amino acid form
• •No bromine modification — unmodified amino acids
• •Gene: NPW (human chr 1p13.3)

Both peptides terminate in -Arg-Phe-NH₂ (RFamide), placing them structurally in the RFamide superfamily alongside neuropeptide FF (NPFF), RFRP-3/GnIH, PrRP, and 26RFa/QRFP — though they bind a receptor family (GPR7/GPR8) phylogenetically related to NPY receptors rather than the NPFF/ORL1/GPR147 family used by other RFamide peptides.

The bromotyrosine modification on NPB-23 is particularly remarkable because enzymatic bromination of tyrosine is uncommon in vertebrates (common in marine invertebrates using peroxidase enzymes). The functional significance of this modification — whether it affects receptor affinity, protease resistance, or biodistribution — is incompletely characterized, though NPB with and without bromination show comparable GPR7 affinity in most binding assays.

Receptor Pharmacology: GPR7 (NPBWR1) and GPR8 (NPBWR2)

GPR7 (NPBWR1) — the primary NPB/NPW receptor:

• •Expressed in both rodents and humans
• •Primary receptor for both NPB and NPW; both forms (23 and 29/30-aa) bind with nanomolar affinity
• •Coupling: Gαi/o (primary); reduces adenylyl cyclase activity, decreases cAMP; activates GIRK channels; inhibits voltage-gated calcium channels
• •Also activates ERK1/2 and p38 MAPK via Gβγ
• •Distribution: predominantly CNS (hypothalamus, brainstem, limbic areas); immune cells

GPR8 (NPBWR2) — rodent-absent receptor:

• •Expressed in humans and other primates but absent in rodents (mouse, rat) — this is a critical translational gap
• •In humans and primates, GPR8 is co-expressed with GPR7 in many hypothalamic areas
• •NPB and NPW bind GPR8 with comparable affinity to GPR7
• •Rodent knockout studies (Npbwr1−/− mice) inform GPR7 biology but cannot model GPR8 contributions, limiting translational inference

Selectivity. NPB and NPW show broadly similar GPR7/GPR8 binding affinities — there is no dramatic selectivity for one receptor over the other from either peptide. This contrasts with the NPY system where Y1, Y2, and Y5 receptors have distinct peptide selectivity profiles. The lack of GPR7 vs. GPR8 selectivity from endogenous ligands means genetic tools (knockout mice) and receptor expression mapping are the primary means of dissecting GPR7 vs. GPR8 biology.

Neuroanatomical Distribution

NPB neuron distribution:

• •Hypothalamus: paraventricular nucleus (PVN), supraoptic nucleus (SON), lateral hypothalamic area (LHA), periventricular nucleus — areas controlling energy balance, HPA axis, and autonomic function
• •Anterior pituitary: NPB-positive cells co-expressing prolactin (lactotrophs) and ACTH (corticotrophs)
• •Brainstem: NTS, parabrachial nucleus — feeding/satiety circuit nodes
• •Spinal cord: dorsal horn — pain modulation
• •Immune cells: expressed in peripheral blood lymphocytes, macrophages

NPW neuron distribution:

• •Similar hypothalamic distribution to NPB, but with some region-specific differences
• •Arcuate nucleus: significant NPW expression; proximity to POMC/NPY energy balance neurons
• •Brain regions relevant to pain and stress: DRG, NTS, LC
• •Testis: NPW expression in Sertoli and Leydig cells

GPR7/NPBWR1 expression:

• •Highly expressed in hypothalamus (ARC, PVN, VMH, LHA)
• •Pituitary (anterior and posterior)
• •Brainstem (NTS, raphe nuclei)
• •Limbic areas (amygdala, hippocampus)
• •Spinal cord dorsal horn
• •Peripheral immune cells

Energy Balance: Orexigenic Central Actions

ICV NPB and NPW stimulate feeding. Central administration of NPB or NPW produces dose-dependent increases in food intake in rodents. The effect is rapid (within 1-2 hours), robust (+50-150% in fasted animals), and partially naloxone-reversible at high doses, suggesting some interaction with opioid pathways. This orexigenic action was among the first functional characterizations of the NPB/NPW system after the 2002 discovery.

Mechanism. The feeding-stimulating effect of central NPW involves:

1. GPR7 activation in LHA: The lateral hypothalamic area contains orexin and MCH neurons. NPW/GPR7 in LHA likely activates orexin neurons, increasing arousal and food motivation.

2. NPY pathway interaction: Hypothalamic NPY neurons express GPR7. NPW/GPR7 activation of NPY neurons would amplify the orexigenic NPY signal — a mechanism supported by c-Fos studies showing NPW activates ARC NPY neuron populations.

3. POMC inhibition: GPR7 on POMC neurons (Gαi coupling → reduced firing) would suppress anorexigenic α-MSH release, indirectly promoting feeding.

Npbwr1−/− knockout phenotype. Mice lacking GPR7 (NPBWR1) develop late-onset obesity on normal chow — a phenotype that has been replicated across multiple knockout lines. The obesity in GPR7-null mice is associated with:

• •Increased white adipose tissue mass
• •Hyperphagia in some (but not all) studies — suggesting both intake and expenditure components
• •Reduced energy expenditure (lower oxygen consumption, reduced BAT thermogenesis in some reports)
• •Impaired glucose metabolism (reduced insulin sensitivity)

This obesity phenotype mirrors the Qrfp−/− mice and Prrp−/− mice phenotypes in being late-onset and partially metabolic-rate-mediated — suggesting GPR7 contributes to hypothalamic energy expenditure tone, not just appetite.

NPB/NPW in diet-induced obesity. In high-fat diet rodent models, hypothalamic NPW expression changes dynamically — early upregulation (adaptive orexigenic drive?) followed by downregulation in sustained obesity. The temporal pattern of NPB/NPW changes in obesity parallels similar dynamics seen with orexin and NPY, suggesting these systems co-regulate the homeostatic response to caloric excess.

HPA Axis and Stress Responses

Central NPW activates the HPA axis. ICV NPW increases plasma ACTH and corticosterone in rats — an effect mediated by CRH neuron activation in the PVN (GPR7 is expressed on PVN CRH neurons). This HPA-activating property is shared with other RFamide peptides (PrRP, 26RFa) and positions NPW as a stress neuropeptide alongside its orexigenic role.

Anxiety-like behavior. NPW-injected rodents show increased anxiety in the elevated plus maze — consistent with HPA/CRH and noradrenergic arousal. Chronic NPW may contribute to sustained anxiety states; GPR7 antagonism has been proposed as an anxiolytic target, though selective antagonists are limited.

Stress-induced eating. The combination of NPW's orexigenic and stress-activating properties positions it as a potential mediator of stress-induced hyperphagia — the drive to consume palatable food during stress, a major contributor to obesity. Whether NPW specifically mediates comfort eating or emotionally-driven food intake is an underexplored research area.

Neuroendocrine and Reproductive Functions

Prolactin regulation. A significant pituitary function of NPB/NPW is prolactin secretion. GPR7 on anterior pituitary lactotrophs responds to NPB/NPW with increased prolactin release. This makes NPB/NPW parallel to PrRP (which also stimulates prolactin from pituitary) — two distinct neuropeptide systems converging on prolactin regulation through different receptors. The physiological context for NPB/NPW-driven prolactin secretion (stress, suckling, fasting) is under investigation.

ACTH and growth hormone. In addition to prolactin, NPW stimulates ACTH release (via PVN CRH neurons → anterior pituitary) and may modulate growth hormone secretion (via somatotroph GPR7 or indirect GHRH/somatostatin effects).

Reproductive axis. GPR7 expression in reproductive tissue (testicular Leydig cells, hypothalamic GnRH neuron proximal areas) suggests NPB/NPW participation in HPG axis regulation. Limited studies indicate NPW can modulate LH secretion, though this function is less characterized than for kisspeptin, GALP, or RFRP-3.

Pain Modulation: Spinal and Supraspinal

GPR7 expression in spinal cord dorsal horn and DRG, combined with central NPB/NPW distribution in pain-processing areas, predicts a pain modulatory role.

Spinal analgesia. Intrathecal NPW produces antinociception in thermal pain tests (hot plate, tail flick) in rodents — an effect blocked by GPR7 antagonists and not GPR8 antagonists, confirming GPR7 as the spinal pain receptor. This spinal analgesic effect resembles that of other neuropeptides acting on dorsal horn Gαi-coupled receptors (enkephalins via DOR, GALP via GALR2, nociceptin via NOP).

Supraspinal effects. As with several RFamide-related peptides, supraspinal NPW injection can produce opposite (hyperalgesic) effects compared to spinal injection — a site-dependent reversal seen with NPFF and 26RFa as well. The supraspinal hyperalgesia may reflect GPR7 on descending facilitatory neurons (ON-cells) in the RVM.

Interaction with opioid systems. Partial naloxone reversal of NPW-induced analgesia suggests interaction with the endogenous opioid system. NPW may enhance enkephalin release or inhibit enkephalin degradation at spinal sites — a mechanism of indirect opioid engagement seen for other neuropeptides.

Immune Modulation: Peripheral GPR7

A distinctive feature of the NPB/NPW system is significant expression in immune cells — peripheral blood lymphocytes, monocytes, and macrophages — and peripheral GPR7 in spleen, lymph node, and thymus.

Lymphocyte function. GPR7 activation on T lymphocytes modulates proliferative responses and cytokine secretion profiles. NPB/NPW shift cytokine balance toward anti-inflammatory outputs in some in vitro models — reducing IL-12 and TNF-α while maintaining IL-10. The net effect is an immunosuppressive tone that could be relevant during stress-associated immune dysregulation.

Macrophage polarization. NPW modulates macrophage activation state, with GPR7/Gαi coupling reducing LPS-stimulated pro-inflammatory cytokine production. This places NPB/NPW in the growing family of neuropeptides that couple the neuroendocrine system to immune regulation (a list that includes VIP, substance P, CGRP, neuropeptide S, and CART).

Clinical relevance. The immune actions of NPB/NPW are underexplored in disease contexts. Inflammatory bowel disease, autoimmune conditions, and sepsis are hypothetical contexts where NPB/NPW immune modulation could be relevant — but no clinical studies have been conducted.

Research Tools and Available Probes

Note: The absence of GPR8 in rodents is a major translational gap — all genetic loss-of-function data is from GPR7 (NPBWR1) knockouts. Understanding GPR8-specific biology requires either primate models or targeted cell-type-specific GPR8 manipulation in human cell lines. The development of GPR7/GPR8 discriminating pharmacological tools is an active but incompletely solved research challenge.

Comparison with Related NPY Family and RFamide Systems

This comparison reveals a pattern: multiple orexigenic neuropeptide systems (NPY, NPB/NPW, QRFP, orexin/hypocretin, MCH) converge on hypothalamic circuits to promote feeding, while fewer anorexigenic systems (PrRP, POMC/CART, GLP-1, PYY) suppress it. The orexigenic excess reflects evolutionary pressure toward energy acquisition. The NPB/NPW system contributes to this orexigenic redundancy while additionally modulating stress and immune systems — a broader functional portfolio than pure feeding signals.

Current Frontiers

GPR7 in obesity pharmacology. Given the Npbwr1−/− obesity phenotype, GPR7 antagonism might be expected to prevent obesity — but the receptor's diverse roles (feeding, stress, immune) create on-target safety concerns. Selective targeting of hypothalamic (vs. immune) GPR7 populations would require either pharmacological CNS/periphery separation or cell-type-targeted approaches.

GPR8 biology in humans. Because GPR8 exists in humans (and primates) but not rodents, human-relevant GPR8 biology must be studied in human cell lines, primate models, or patient samples. Whether GPR8 has distinct feeding, stress, or immune roles from GPR7 is largely unknown — an important gap given that drugs targeting the NPB/NPW system would engage both receptors in humans.

NPB/NPW in reproductive medicine. The pituitary prolactin-stimulating and potential GnRH-modulating effects suggest NPB/NPW involvement in lactation and reproductive disorders. Whether NPB/NPW contributes to hyperprolactinemia states or fertility impairment warrants investigation.

Biased agonism at GPR7. Like other Gαi-coupled receptors, GPR7 likely supports biased agonism — selective G protein vs. β-arrestin signaling. Biased GPR7 agonists that preserve analgesia (potentially Gαi-mediated) while reducing HPA/feeding effects (potentially β-arrestin or distinct Gαi subtypes) represent a speculative but conceptually interesting research direction.

Bromotyrosine significance. The unique bromination of NPB is unexplained in functional terms. Comparative studies of brominated vs. non-brominated NPB-23 at GPR7/8, using mass spectrometry-guided metabolic stability assays and bias profiling, could reveal whether this unusual modification confers functional properties that justify the energetic cost of enzymatic bromination.

Conclusion

Neuropeptide B and neuropeptide W are GPR7/GPR8 ligands discovered in 2002 at the convergence of the RFamide superfamily and the NPY receptor phylogeny, combining orexigenic hypothalamic actions with HPA-activating stress properties and peripheral immune modulation. The Npbwr1−/− obesity phenotype establishes GPR7 as a regulator of both feeding behavior and energy expenditure, while the bromotyrosine modification on NPB remains a unique biochemical puzzle. The absence of GPR8 in rodents creates a significant translational gap that must be addressed for any GPR7/GPR8-targeted drug program. As selective pharmacological tools for GPR7 vs. GPR8 are developed and human receptor biology is better characterized, NPB and NPW are likely to reveal additional circuit-level and peripheral functions that expand their significance beyond the initial orexigenic and neuroendocrine findings.

Key Research References

• •Shimomura Y, Harada M, Goto M, et al. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem. 2002;277(39):35826-35832. PMID: 12130646
• •Tanaka H, Yoshida T, Miyamoto N, et al. Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. Proc Natl Acad Sci USA. 2003;100(10):6251-6256. PMID: 12730363
• •Mondal MS, Yamaguchi H, Date Y, et al. Neuropeptide W is present in the rat hypothalamus and has a potent orexigenic effect. Regul Pept. 2003;114(2-3):97-103. PMID: 12832099
• •Ishii M, Fei H, Friedman JM. Targeted disruption of GPR7, the endogenous receptor for neuropeptides B and W, leads to metabolic defects and adult-onset obesity. Proc Natl Acad Sci U S A. 2003;100(18):10540-10545. PMID: 12925742

---

This article is intended for Research Use Only (RUO). Neuropeptide B, neuropeptide W, GPR7/GPR8 ligands, and related analogs are not approved for human therapeutic use. Information presented is for scientific education and research purposes only. Peptides.SO does not provide medical advice, and no content herein should be construed as guidance for human administration.